M Blennow1, K Sävman, P Ilves, M Thoresen, L Rosengren. 1. Department of Paediatrics, Huddinge University Hospital and Neonatal Programme, Astrid Lindgren's Children's Hospital, Karolinska Institutet, Stockholm, Sweden. mats.blennow@kbh.ki.se
Abstract
UNLABELLED: Upcoming trials of neuroprotective strategies in severely asphyxiated newborn infants emphasize the need for early and objective markers of both good and bad long-term prognosis. Traditional markers such as neurological depression and seizures are not specific. AIM: To study whether measurement in the cerebrospinal fluid of some proteins known to be specific to the central nervous system was in covariance with the clinical course and long-term prognosis. METHODS: Twenty-two asphyxiated infants were included in the study and compared with a control group of 8 infants without signs of perinatal asphyxia. Cerebrospinal fluid (CSF) was collected during the first 4 d of life and analysed for neurofilament protein (NFp), glial fibrillary acidic protein (GFAp), protein S-100 and neuron-specific enolase (NSE). RESULTS: The concentrations of all four proteins were significantly increased in the CSF of asphyxiated infants. The concentrations correlated significantly with other indicators of long-term prognosis and to neurological impairment at I y of age, or death before that time. Specifically, concentrations were excessively high in the five infants who died. CONCLUSIONS: High concentrations of brain-specific proteins are released into the CSF of asphyxiated infants. It might therefore be useful to measure these concentrations when excluding patients with the gravest prognosis from neuroprotective trials.
UNLABELLED: Upcoming trials of neuroprotective strategies in severely asphyxiated newborn infants emphasize the need for early and objective markers of both good and bad long-term prognosis. Traditional markers such as neurological depression and seizures are not specific. AIM: To study whether measurement in the cerebrospinal fluid of some proteins known to be specific to the central nervous system was in covariance with the clinical course and long-term prognosis. METHODS: Twenty-two asphyxiated infants were included in the study and compared with a control group of 8 infants without signs of perinatal asphyxia. Cerebrospinal fluid (CSF) was collected during the first 4 d of life and analysed for neurofilament protein (NFp), glial fibrillary acidic protein (GFAp), protein S-100 and neuron-specific enolase (NSE). RESULTS: The concentrations of all four proteins were significantly increased in the CSF of asphyxiated infants. The concentrations correlated significantly with other indicators of long-term prognosis and to neurological impairment at I y of age, or death before that time. Specifically, concentrations were excessively high in the five infants who died. CONCLUSIONS: High concentrations of brain-specific proteins are released into the CSF of asphyxiated infants. It might therefore be useful to measure these concentrations when excluding patients with the gravest prognosis from neuroprotective trials.
Authors: Lina F Chalak; Pablo J Sánchez; Beverley Adams-Huet; Abbot R Laptook; Roy J Heyne; Charles R Rosenfeld Journal: J Pediatr Date: 2013-12-12 Impact factor: 4.406
Authors: Ericka L Fink; Rachel P Berger; Robert S B Clark; R Scott Watson; Derek C Angus; Ashok Panigrahy; Rudolph Richichi; Clifton W Callaway; Michael J Bell; Stefania Mondello; Ronald L Hayes; Patrick M Kochanek Journal: Resuscitation Date: 2016-02-06 Impact factor: 5.262
Authors: Christopher S Ennen; Thierry A G M Huisman; William J Savage; Frances J Northington; Jacky M Jennings; Allen D Everett; Ernest M Graham Journal: Am J Obstet Gynecol Date: 2011-06-15 Impact factor: 8.661
Authors: An N Massaro; Andreas Jeromin; Nadja Kadom; Gilbert Vezina; Ronald L Hayes; Kevin K W Wang; Jackson Streeter; Michael V Johnston Journal: Pediatr Crit Care Med Date: 2013-03 Impact factor: 3.624
Authors: Sahra Abdulle; Asa Mellgren; Bruce J Brew; Paola Cinque; Lars Hagberg; Richard W Price; Lars Rosengren; Magnus Gisslén Journal: J Neurol Date: 2007-04-10 Impact factor: 6.682